Related Experiment Video
Updated: Oct 6, 2025
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.8K
Teucrium polium: Potential Drug Source for Type 2 Diabetes Mellitus.
Yaser Albadr1, Andrew Crowe1, Rima Caccetta1
1Curtin Medical School, Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Bentley, WA 6102, Australia.
Biology
|January 21, 2022
Summary
This review explores Teucrium polium (Tp) for type 2 diabetes management. Its flavonoids may lower glucose and enhance insulin secretion, offering potential for new antidiabetic treatments.
Area of Science:
- Pharmacology and Phytomedicine
- Endocrinology and Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) prevalence is increasing globally, posing a significant public health challenge.
- Current T2DM treatments require augmentation, necessitating novel therapeutic strategies.
- Medicinal plants have historically contributed to drug discovery, including antidiabetic agents.
Purpose of the Study:
- To review the glucose-lowering effects of Teucrium polium (Tp).
- To investigate Tp's role in insulin secretion from pancreatic beta-cells.
- To analyze the contribution of key flavonoids in Tp extracts to its antidiabetic potential.
Main Methods:
- Literature review of existing studies on Teucrium polium and its constituents.
- Analysis of in vitro and in vivo data regarding glucose levels and insulin secretion.
- Examination of the chemical composition of Tp extracts, focusing on flavonoids like apigenin, quercetin, and rutin.
Main Results:
- Teucrium polium extracts demonstrate significant blood glucose-lowering effects.
- Tp has been shown to induce insulin secretion from pancreatic beta-cells in vitro.
- Flavonoids, including apigenin, quercetin, and rutin, are implicated as key active compounds.
Conclusions:
- Teucrium polium exhibits promising antidiabetic properties, particularly in glucose regulation and insulin secretion.
- The identified flavonoids are potential therapeutic agents for type 2 diabetes mellitus.
- Further research into Tp's constituents could lead to the development of novel antidiabetic drugs.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
462
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
462
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
332
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
332
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
306
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
306
01:17Oral Hypoglycemic Agents: Sulfonylureas
381
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
381
01:15Diabetes: Management and Pharmacotherapy
430
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
430
01:36Carbohydrate Metabolism
12.3K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
12.3K